Market Overview

UPDATE: Wedbush Lowers Medifast's PT

Related MED
Events Scheduled for Week of Jun. 16th to Jun. 20th
Medifast (MED) Falls: Stock Goes Down 7.1% - Tale of the Tape

According to a research report published this morning, Wedbush has lowered Medifast's (NYSE: MED) PT from $23 to $22.

In the report, Wedbush commented, "Return to double-digit growth in direct-selling business leads to revenue upside. Q1 revenues of $89 million exceeded the consensus estimate of $87 million on 13% growth in Take Shape for Life, the direct-selling arm, to $53 million, due to a 2% increase in active health coaches and 3% increase in productivity."

Wedbush maintains its Outperform rating on Medifast, which is currently trading at $16.57.

Posted-In: WedbushAnalyst Color Price Target Analyst Ratings

 

Most Popular

Related Articles (MED)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free